Across these studies, the efficacy of nivolumab in treating advanced cervical cancer is evident, with the variations in the response rates and survival outcomes likely reflecting the differences in patient populations, treatment regimens, and PD-L1 status. This evidence concerns the gene CD274 and cervical carcinoma.